Literature DB >> 27641986

Host - hepatitis C viral interactions: The role of genetics.

Markus H Heim1, Pierre-Yves Bochud2, Jacob George3.   

Abstract

Hepatitis C virus (HCV) is a major cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of patients can clear the virus spontaneously. Elimination of HCV during acute infection correlates with a rapid induction of innate, especially interferon (IFN)-induced genes, and a delayed induction of adaptive immune responses. There is a strong association between genetic variants in the IFNλ (IL28B) locus with the rate of spontaneous clearance. Individuals with the ancestral IFNλ4 allele capable of producing a fully active IFNλ4 are paradoxically not able to clear HCV in the acute phase and develop chronic hepatitis C (CHC) with more than 90% probability. In the chronic phase of HCV infection, the wild-type IFNλ4 genotype is strongly associated with an induction of hundreds of classical type I/type III IFN stimulated genes in hepatocytes. However, the activation of the endogenous IFN system in the liver is ineffective in clearing HCV, and is even associated with impaired therapeutic responses to pegylated (Peg)IFNα containing treatments. While the role of genetic variation in the IFNλ locus to the outcome of CHC treatment has declined, it is clear that variation not only at this locus, but also at other loci, modulate clinically important liver phenotypes, including inflammation, fibrosis progression and the development of hepatocellular cancer. In this review, we summarize current knowledge about the role of genetics in the host response to viral hepatitis and the potential future evolution of knowledge in understanding host-viral interactions.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD8(+) T cells; Fibrosis; GWAS; Haplotypes; Hepatitis C virus; Hepatocellular cancer; IL28B; Innate immunity; Interferon; Jak-STAT; T cell exhaustion; Viral escape

Mesh:

Substances:

Year:  2016        PMID: 27641986     DOI: 10.1016/j.jhep.2016.07.037

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

Review 1.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

2.  The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?

Authors:  Eric G Meissner
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

3.  Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.

Authors:  Hawwa Alao; Maggie Cam; Chithra Keembiyehetty; Fang Zhang; Elisavet Serti; Daniel Suarez; Heiyoung Park; Nicolaas H Fourie; Elizabeth C Wright; Wendy A Henderson; Qisheng Li; T Jake Liang; Barbara Rehermann; Marc G Ghany
Journal:  Hepatology       Date:  2018-07-16       Impact factor: 17.425

4.  SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Authors:  Tanja Blumer; Mairene Coto-Llerena; Francois H T Duong; Markus H Heim
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

5.  The role of genetics in hepatic fibrosis among hepatitis C virus patients.

Authors:  Heiyoung Park; Thomas R O'Brien; Barbara Rehermann
Journal:  Hepatology       Date:  2018-03-25       Impact factor: 17.425

6.  Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.

Authors:  Hala Rady Ahmed; Nancy G F M Waly; Rehab Mahmoud Abd El-Baky; Ramadan Yahia; Helal F Hetta; Amr M Elsayed; Reham Ali Ibrahem
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

Review 7.  Type III Interferons in Hepatitis C Virus Infection.

Authors:  Maude Boisvert; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2016-12-23       Impact factor: 7.561

8.  The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.

Authors:  Jake R Morgan; Arthur Y Kim; Susanna Naggie; Benjamin P Linas
Journal:  Open Forum Infect Dis       Date:  2017-12-08       Impact factor: 4.423

9.  CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study.

Authors:  María Ángeles Jiménez-Sousa; Ana Zaida Gómez-Moreno; Daniel Pineda-Tenor; Luz Maria Medrano; Juan José Sánchez-Ruano; Amanda Fernández-Rodríguez; Tomas Artaza-Varasa; José Saura-Montalban; Sonia Vázquez-Morón; Pablo Ryan; Salvador Resino
Journal:  Clin Transl Med       Date:  2017-07-28

10.  Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.

Authors:  Narayan Ramamurthy; Emanuele Marchi; M Azim Ansari; Vincent Pedergnana; Angela Mclean; Emma Hudson; Rory Bowden; Chris C A Spencer; Eleanor Barnes; Paul Klenerman
Journal:  Hepatology       Date:  2018-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.